While many companies enjoyed stellar share price rises over 2017, separating those that will continue to climb in the next year from those that may retrace is no easy task for investors. But here are two companies that I think have a better chance than most of falling into the former category.
Today's Q1 trading update from £1.3bn cap specialised technical products and services supplier Diploma (LSE:DPLM) gives some indication as to why the company became rather popular with investors over the second half of last year.
Shares in FTSE 250 pharmaceutical group Indivior (LSE:INDV) have risen by 177% since the firm was spun out of consumer goods firm Reckitt Benckiser at the end of 2014.
However, it hasn't been a smooth ride for investors in this opioid addiction treatment specialist. The shifting tides of the firm's legal battles against generic competitors have caused whiplash movements in the share price. A strong nerve has been required to continue holding.
Dr Martin Court, Executive Director, has transferred in 934 shares in the company on the 15th December 2017 at a price of 0.00p. The Director now holds 1,802 shares representing 0.00% of the shares in issue.